![PDF) Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: Insights from two clinical trials on turoctocog alfa PDF) Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: Insights from two clinical trials on turoctocog alfa](https://www.researchgate.net/profile/Alfonso-Iorio/publication/259958630/figure/tbl1/AS:669161948708868@1536552049354/Baseline-scores-mean-changes-and-percentage-of-responders-for-HAEMO-QOL-dimension-and_Q320.jpg)
PDF) Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: Insights from two clinical trials on turoctocog alfa
![Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish - Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish -](https://onlinelibrary.wiley.com/cms/asset/ff398181-0a71-4f58-91a2-95a4529c72bf/hae13883-fig-0002-m.jpg)
Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish -
![PDF) A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A PDF) A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A](https://i1.rgstatic.net/publication/321635319_A_Pharmacometric_Approach_to_Substitute_for_a_Conventional_Dose-Finding_Study_in_Rare_Diseases_Example_of_Phase_III_Dose_Selection_for_Emicizumab_in_Hemophilia_A/links/5a2c16c30f7e9b63e53ad4a2/largepreview.png)
PDF) A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A
![Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in](https://onlinelibrary.wiley.com/cms/asset/5531a4df-1789-40af-bc2c-5190f7db6c14/rth212674-fig-0001-m.jpg)
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in
![PDF) The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients with Severe Hemophilia A: A Retrospective Analysis from the ReCARE Study PDF) The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients with Severe Hemophilia A: A Retrospective Analysis from the ReCARE Study](https://www.researchgate.net/profile/Rongfu-Zhou/publication/311448132/figure/fig1/AS:634949791137794@1528395235963/Study-flow-chart_Q320.jpg)
PDF) The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients with Severe Hemophilia A: A Retrospective Analysis from the ReCARE Study
![Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish - Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish -](https://onlinelibrary.wiley.com/cms/asset/599b8950-eb3c-4405-baca-24ca6f574576/hae13883-fig-0003-m.jpg)
Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish -
![PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial | ResearchGate PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial | ResearchGate](https://www.researchgate.net/publication/342373543/figure/tbl2/AS:906005986693121@1593020068874/Details-of-Bleeding-Episodes-and-Hemostatic-Response-to-Turoctocog-Alfa-Treatment_Q320.jpg)
PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial | ResearchGate
![PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial | ResearchGate PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial | ResearchGate](https://i1.rgstatic.net/publication/342373543_Safety_and_Efficacy_of_Turoctocog_Alfa_in_the_Prevention_and_Treatment_of_Bleeding_Episodes_in_Previously_Treated_Patients_from_China_with_Severe_Hemophilia_A_Results_from_the_Guardian_7_Trial/links/5ef38d51a6fdcceb7b200c43/largepreview.png)
PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial | ResearchGate
![A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A. - Abstract - Europe PMC A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6061395/bin/40262_2017_616_Fig2_HTML.jpg)
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A. - Abstract - Europe PMC
Interim results from a large multinational extension trial (guardian <sup>â—¢</sup>2) using turoctocog alfa for p
![PDF) Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial PDF) Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial](https://i1.rgstatic.net/publication/328784719_Long-term_safety_and_efficacy_of_turoctocog_alfa_in_prophylaxis_and_treatment_of_bleeding_episodes_in_severe_haemophilia_A_Final_results_from_the_guardian_2_extension_trial/links/5be2e75e4585150b2ba57d18/largepreview.png)
PDF) Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial
![PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial | ResearchGate PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial | ResearchGate](https://www.researchgate.net/publication/342373543/figure/tbl1/AS:906005986672640@1593020068849/Demographics-and-Baseline-Characteristics_Q320.jpg)
PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial | ResearchGate
![A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A | SpringerLink A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40262-017-0616-3/MediaObjects/40262_2017_616_Fig3_HTML.gif)
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A | SpringerLink
![PDF) Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: Insights from two clinical trials on turoctocog alfa PDF) Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: Insights from two clinical trials on turoctocog alfa](https://www.researchgate.net/profile/Alfonso-Iorio/publication/259958630/figure/fig2/AS:282610627563549@1444391032367/Mean-change-in-HAEMO-QOL-total-score-for-each-version-from-baseline-to-end-of-treatment_Q320.jpg)
PDF) Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: Insights from two clinical trials on turoctocog alfa
![Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in](https://onlinelibrary.wiley.com/cms/asset/7989f32a-98f7-4c40-ad31-22f393ba42fa/rth212674-fig-0003-m.jpg)
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in
![PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial | ResearchGate PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial | ResearchGate](https://www.researchgate.net/publication/342373543/figure/fig1/AS:906005986697220@1593020068821/Participant-flow-Notes-a-3-screening-failures-1-patient-did-not-meet-the-inclusion_Q320.jpg)
PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial | ResearchGate
![Dragana JANIC | MD PhD Professor | University Children's Hospital, Belgrade, Serbia, Belgrade | Hematology and Oncology Dragana JANIC | MD PhD Professor | University Children's Hospital, Belgrade, Serbia, Belgrade | Hematology and Oncology](https://www.researchgate.net/publication/355672474/figure/fig4/AS:1083587373858816@1635358770033/Cumulative-survival-of-children-with-brain-tumors-according-to-extent-of-the-disease_Q320.jpg)
Dragana JANIC | MD PhD Professor | University Children's Hospital, Belgrade, Serbia, Belgrade | Hematology and Oncology
![PDF) The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients with Severe Hemophilia A: A Retrospective Analysis from the ReCARE Study PDF) The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients with Severe Hemophilia A: A Retrospective Analysis from the ReCARE Study](https://i1.rgstatic.net/publication/311448132_The_Efficacy_of_Recombinant_FVIII_Low-Dose_Prophylaxis_in_Chinese_Pediatric_Patients_with_Severe_Hemophilia_A_A_Retrospective_Analysis_from_the_ReCARE_Study/links/5d9cc2ea92851c2f70f713cb/largepreview.png)
PDF) The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients with Severe Hemophilia A: A Retrospective Analysis from the ReCARE Study
![Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial - Lentz - 2018 - Haemophilia - Wiley Online Library Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial - Lentz - 2018 - Haemophilia - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/fdb6088b-9d26-4db2-8599-d94ce478e5be/hae.2018.24.issue-6.cover.jpg?trick=1663635686417)
Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial - Lentz - 2018 - Haemophilia - Wiley Online Library
![A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A. - Abstract - Europe PMC A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6061395/bin/40262_2017_616_Fig4_HTML.jpg)